Progressive multifocal leukoencephalopathy (PML) is a rare and severe demyelinating disease of the white matter in the central nervous system (CNS), and is caused by the John Cunningham virus. Most PML cases occur in immunocompromised patients, particularly those with impaired cellmediated immunity. There is no specific therapy for PML; the main therapeutic approach is restoring host adaptive immune responses. In 2005, PML was described in two multiple sclerosis (MS) patients treated with natalizumab. MS is a chronic inflammatory demyelinating disease of the CNS that has been suggested to be associated with attacks by autoreactive lymphocytes. Disease-modifying therapies have recently been shown to reduce the frequency and severity of clinical relapse, and slow the development of disability. Although freedom from disease activity has become the primary aim of the treatment of MS, these therapies increase the risk of PML. Natalizumab is a monoclonal immunoglobulin antibody directed toward a4 integrin adhesion molecules. To date, 731 natalizumab-associated PML cases (728 MS and three Crohn's disease) have been reported, including one case of PML in a Japanese patient with MS. Fingolimod is a sphingosine 1-phosphate receptor modulator that prevents the egress of lymphocytes from lymphatic tissue. There have been 15 confirmed fingolimod-associated PML cases, including four cases in Japanese MS patients. Dimethyl fumarate is the methyl ester of fumaric acid. The anti-inflammatory mechanism of dimethyl fumarate has not yet been elucidated in detail. A total of 21 cases of PML have been reported in patients receiving dimethyl fumarate, among which five were MS patients. Dimethyl fumarate-associated PML has not been documented in Japan. In the era of disease-modifying therapies for the treatment of MS, neurologists need to consider drug-induced PML in MS.
Introduction
Progressive multifocal leukoencephalopathy (PML) is a rare and potentially fatal infectious disease of the central nervous system (CNS) that is caused by the JC virus (JCV). It was named after the initials of the first patient (John Cunningham). Reactivated JCV infection against oligodendrocytes, astrocytes and neurons results in severe demyelination. PML occurs almost exclusively in immunocompromised patients, particularly those with impaired cell-mediated immunity. 1 As the name implies, PML typically manifests with subacute and progressive neurological deficits, including cognitive dysfunction, dysarthria, motor deficits (hemiplegia or quadriplegia), cerebellar symptoms and visual symptoms. The diagnosis of PML is based on clinical, radiological, pathological and molecular analyses, such as the detection of JCV DNA by polymerase chain reaction in the cerebrospinal fluid. 2, 3 However, brain biopsy is the gold standard for its diagnosis. 2, 3 There is no specific therapy for PML, and it has a high mortality rate. The main therapeutic approach is restoring host adaptive immune responses. This therapeutic strategy differs according to the clinical setting. 4 Anti-retroviral therapy is recommended for PML patients with human immunodeficiency virus (HIV) infection. The withdrawal of immunosuppressive drugs, if possible, needs to be considered for PML patients without HIV infection. Monoclonal antibodies need to be discontinued and plasma exchange (PLEX) started for PML patients using monoclonal antibodies, such as natalizumab-associated PML. The successful restoration of immunity often leads to immune reconstitution inflammatory syndrome (IRIS), which is neurological deterioration associated with brain swelling and the risk of herniation on magnetic resonance imaging (MRI) of the head. IRIS is also associated with mortality rates and functional disability, and treatments with glucocorticoids are necessary when IRIS is suspected.
Progressive multifocal leukoencephalopathy was initially reported as a rare disease in patients with hematological malignancies, such as chronic lymphocytic leukemia, chronic myeloid leukemia and Hodgkin lymphoma. 5 PML was then recognized as a major opportunistic infection associated with acquired immune deficiency syndrome (AIDS), with a prevalence of 1-5%. 6, 7 Since the widespread use of anti-retroviral therapy, the incidence of PML in AIDS patients has decreased, 8 with a prevalence of 1.3 cases/1000 patients-years at risk (95% CI 0.8-1.9) between 2000 and 2006. PML has also been reported in patients with solid organ malignancies, granulomatous and inflammatory diseases, autoimmune diseases, and solid organ transplant recipients, and even in patients with minimal or occult immunosuppression, such as hepatic cirrhosis and renal failure. 9, 10 Approximately 85% of PML patients in the USA and Europe currently have AIDS as an underlying disease. 6 In contrast, underlying diseases vary in Japan. For example, 55 PML patients were identified between 1 April 2011 and 31 March 2013; the underlying diseases were hematological malignancies (n = 14; 25%), HIV infection (n = 13; 24%), autoimmune diseases (n = 13; 24%), organ transplantation (n = 5; 9%), other diseases (n = 9; 16%) and unknown (n = 1; 2%).
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In 2005, concerns were expressed regarding PML, because it was identified in two patients with multiple sclerosis (MS) and one patient with Crohn's disease treated with natalizumab. [11] [12] [13] Based on these studies, the contribution of therapeutic agents to the pathogenesis of PML has been widely accepted.
Drug-induced PML
Progressive multifocal leukoencephalopathy has traditionally been associated with immunocompromised conditions; therefore, many drugs, such as corticosteroids and antineoplastic agents, could contribute to its development. In addition, many biological products, including monoclonal antibodies (e.g. natalizumab and rituximab), have been approved and introduced into clinical practice in the past several years. Although these biological products have excellent therapeutic efficacy, several drugs have been reported to cause PML. The link between these drugs and PML has provided novel insights into the pathogenesis of PML. Table 1 shows the reported drugs associated with PML. [14] [15] [16] A large number of these immunosuppressive/immunomodulatory drugs are considered to increase the risk of developing PML. Marked differences have been found in the frequency of developing PML, the nature of the underlying diseases being treated and the time from the initiation of the drug to the development of PML among these drugs. Zaheer et al. 17 presented the classes of agents predisposing patients to PML as follows. Class 1: therapeutic agents that result in an unequivocally and markedly increased risk of PML. These agents are associated with PML in patients who have no known disorder that predisposes them to PML. They are also associated with a latency of many months to years from the time of initiation to the onset of PML. To date, two agents have been identified: natalizumab and efalizumab. Class 2: therapeutic agents that appear to increase the Table 2) . 18 As MS is not a disease that predisposes patients to PML, DMT used in the treatment of MS are classified into higher categories in this classification. Natalizumab is classified as class I, a high potential risk of PML; and fingolimod and dimethyl fumarate are both classified as class II, a low potential risk of PML. Other DMT, such as alemtuzumab and rituximab, are classified as class III, no or a very low potential risk of PML.
Drug-induced PML in MS
Multiple sclerosis is a chronic inflammatory demyelinating disease of the CNS that has been suggested to be associated with attacks by autoreactive peripheral lymphocytes crossing the blood-brain barrier, resulting in significant inflammation, demyelination, gliosis and axonal damage. 19 MS affects gray as well as white matter. Despite some patients with relapsingremitting MS (RRMS) having a benign disease course, most RRMS patients, which is the most common form of MS and constitutes 85% of those diagnosed with MS, show increasingly more severe disabilities over time and eventually convert to secondary progressive MS. In addition, in primary progressive MS, symptoms are typically ongoing rather than acute attacks and remission, and occur in 15% of patients with MS; this form is less frequent in Japan. Although there is still no curative treatment, nine different DMT have become available for the treatment of MS worldwide, including interferon-b, glatiramer acetate, dimethyl fumarate, natalizumab, fingolimod, teriflunomide, alemtuzumab, mitoxantrone and ocrelizumab. These DMT have been confirmed to help prevent the formation of inflammatory lesions, decrease the frequency and severity of clinical relapse, and slow the development of disability. As all of these approved drugs exert antiinflammatory effects, they might be more effective in the early phases of disease development. [20] [21] [22] Although traditional DMT for MS, such as interferon-b and glatiramer acetate, delay disease progression and reduce disease activity on brain MRI to varying degrees, they have not been shown to induce disease remission. With the development of more effective DMT in the past several years, the aim of MS treatment has shifted from simply reducing relapse rates and slowing disability progression to preventing all evidence of new disease activity. 23 Freedom from disease activity, also referred to as no evidence of disease activity (NEDA), has become the primary aim of the treatment of MS. NEDA for MS is currently a composite of three or four related measures of disease activity. NEDA-3 includes: (i) no relapse; (ii) no disability progression; and (iii) no MRI activity (new or enlarging T2 lesions or gadolinium [Gd]-enhanced lesions). NEDA-4 added brain volume loss to NEDA-3. [23] [24] [25] However, these successful immunotherapies lead to an increased risk of unexpected complications, such as PML.
Although MS is known as an autoimmune disease in the CNS and a large number of MS patients have been treated with immunosuppressive drugs, such as high-dose corticosteroids, azathioprine and mitoxantrone, no PML case in MS patients had been observed until the occurrence of PML cases in MS patients treated with natalizumab and interferon-b was reported in 2005.
12,13 MS itself is not an underlying disease of PML. However, in the era of new DMT for the treatment of MS, we need to consider PML as a possible differential diagnosis when new white matter lesion(s) are observed on brain MRI in MS patients receiving DMT.
Natalizumab
Natalizumab is a humanized monoclonal immunoglobulin G4 antibody directed toward a4 integrin adhesion molecules that prevents the migration of immune cells across the blood-brain barrier, and has been approved for the treatment of RRMS with strong efficacy. 26 Phase III trials on RRMS found that natalizumab reduced the annualized relapse rate (ARR) by 68%, the disability progression rate by 54% and MRI Gd-enhancing lesions by >80% than that with a placebo. 26 A systematic review of trials evaluating natalizumab for RRMS, and pooled data from natalizumab safety and efficacy in RRMS (AFFIRM) and safety and efficacy of natalizumab in combination with interferon beta1a in patients with RRMS (SENTINEL) showed that natalizumab significantly reduced the risk of relapse during 2 years (relative risk 0.57, 95% CI 0.47-0.89). 27 Natalizumab was approved by the US Food and Drug Administration (FDA) in 2004, but was suspended from the market in 2005 because of the occurrence of PML. 12, 13 However, it was reintroduced in 2006 by the FDA as a second-line or thirdline therapy with additional precautions, including mandatory risk mitigation and a restriction to RRMS patients with high disease activity, and was approved in 2006 by the European Medicines Agency. Natalizumab has been available in Japan since 2014.
Although natalizumab is well tolerated, treatments with it increase the risk of developing PML. As of 31 May 2017, approximately 170 900 patients received natalizumab in the post-marketing setting worldwide, and as of 6 June 2017, there have been 731 confirmed natalizumab-associated PML cases (728 MS and three Crohn's disease). 28 In addition, one natalizumab-associated PML case in a Japanese MS patient was documented in 2016.
The risk of developing natalizumab-associated PML depends on three factors: (i) the presence of anti-JCV antibodies; (ii) a long treatment duration, particularly that longer than 24 months; and (iii) the administration of prior immunosuppressive drugs (e.g. mitoxantrone, azathioprine, methotrexate, cyclophosphamide and mycophenolate mofetil). 28 As of 31 May 2017, the global overall incidence of natalizumab-associated PML patients was 4.21 per 1000 patients (95% CI 3.91-4.52 per 1000 patients); 28 however, the incidence of PML in MS patients with the three risk factors described above increased to 11.1 out of 1000 patients. 29 In addition, the JCV antibody index (AI) has been recognized as a predictive marker for the development of PML. Therefore, PML risk estimates including stratification by the anti-JCV AI threshold have been adopted (Fig. 1) . 30 The overall survival rate of natalizumab-associated PML is 70-75%. 28 Although this survival rate is superior to that for HIV-PML, patients who survive natalizumab-associated PML have serious morbidities associated with permanent disability. 31 Furthermore, PML might be detected in the pre-symptomatic phase using routine surveillance brain MRI, termed "asymptomatic PML," and the early detection and treatment of asymptomatic PML can lead to favorable outcomes. An analysis of 336 patients who developed natalizumab-associated PML showed that 77.2% survived during a mean follow up of 16.1 months from the diagnosis of PML. High survival rates were shown in asymptomatic PML patients in that study as follows: overall survival was 96.7% for asymptomatic PML and 75.4% for symptomatic PML. However, PLEX was carried out for 80% of asymptomatic PML patients, and IRIS occurred in 66.7%.
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Brain MRI is the most sensitive diagnostic tool for the detection of PML lesions, even in the asymptomatic phase. Traditional symptomatic PML lesions, such as in HIV-PML, typically appear as hypointense areas on T1-weighted images, and hyperintense areas on T2-weighted images and fluid-attenuated inversion recovery sequences. Fluid-attenuated inversion recovery is considered to be the most sensitive sequence for detecting PML lesions. In addition, new PML lesions are observed as hyperintense areas on diffusion-weighted images. PML lesions are generally multifocal, localize predominantly to supratentorial subcortical white matter, and can involve the basal ganglia, brainstem and cerebellum. 31 PML lesions do not generally show Gd enhancement (approximately 15% with positive enhancement) or develop surrounding edema. In contrast, Gd enhancement and surrounding edema are observed in PML-IRIS. Although brain MRI findings for symptomatic natalizumab-associated PML are similar to those of classical PML described above, characteristic findings for symptomatic natalizumab-associated PML are suspected. Large lesions >3 cm, a subcortical localization, lesion(s) with a sharp border toward the gray matter and an ill-defined border toward the white matter, and the presence of Gd enhancement are more frequent findings on brain MRI than with classical PML. Among these findings, the predominance of subcortical lesion involvement and frequent contrast enhancement in affected lesions (approximately 40% with positive enhancement) are reported as characteristic findings of symptomatic natalizumab-associated PML. 32 In contrast, several patterns of natalizumab-associated PML lesions on brain MRI have also been found, making it difficult to exclude PML when new MRI lesions develop in MS patients treated with natalizumab. [33] [34] [35] [36] An early diagnosis, particularly in the asymptomatic phase, is important because of the associated favorable outcome. Brain MRI findings in asymptomatic natalizumab-associated PML are more likely to be monofocal, and localized to cortical white matter. Diffusion-weighted images hyperintensity and the involvement of U fibers have been suggested as characteristic findings. 35 In addition, a punctate pattern is a promising MRI finding for asymptomatic natalizumab-associated PML. 35, 36 A punctate pattern is also observed in perilesional affected areas in symptomatic natalizumab-associated PML and PML-IRIS. 33, 35, 36 The punctate pattern also helps differentiate asymptomatic PML lesions from asymptomatic MS lesions on MRI. 37 Several MRI findings of natalizumab-associated PML are shown in Fig. 2 . [33] [34] [35] [36] The early detection of natalizumab-associated PML, followed by the rapid cessation of natalizumab therapy and PLEX (excluding asymptomatic natalizumabassociated PML) to restore immune function appears to be associated with favorable outcomes. [38] [39] [40] [41] [42] Immune reconstitution inflammatory syndrome occurs in more natalizumab-associated PML patients within days or several weeks after the withdrawal or removal of natalizumab by PLEX than in HIV-PML patients. 43 Thus, the cessation of natalizumab, a course of PLEX, and intravenous methylprednisolone for the treatment of IRIS are recommended for symptomatic natalizumab-associated PML. Although PLEX has been carried out for many natalizumabassociated PML patients, a previous study reported that there was no evidence for its clinical benefits. 44 Therefore, definitive evidence for the treatment of natalizumab-associated PML is required. Furthermore, as IRIS is critical for mortality and disability, PLEX is not recommended for asymptomatic natalizumab-associated PML.
An algorithm for MRI-based PML safety monitoring has been proposed for the management of MS patients treated with natalizumab (Fig. 3) . 45, 46 Fingolimod Fingolimod is an oral sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phosphate receptors on lymphocytes and prevents them from exiting lymphatic tissue. Therefore, it blocks autoreactive lymphocyte invasion from the lymph nodes to the CNS. 47 Fingolimod has been suggested to have neuroprotective properties because it is able to enter the CNS, and bind to neurons and glia expressing sphingosine 1-phosphate receptors. Although circulating lymphocytes are decreased, immune function remains largely unaffected. 48 Previous findings suggested that fingolimod is selective for lymphocyte sequestration targeting na€ ıve T cells and central memory T cells, while allowing a subset of effective memory cells to maintain normal function. 49 Two phase III trials on RRMS showed that fingolimod reduced ARR by 48-55%, the disability progression rate by 25-30% and MRI Gd-enhanced lesions by approximately 80% from that with a placebo. 50, 51 Another study comparing it with interferon-b-1a also reported a reduction in ARR by 52%, a reduced rate of disability progression by 25% and a reduction in MRI Gd-enhanced lesions by >50% in fingolimod-treated RRMS patients. 52 Common adverse events were upper respiratory tract infections, headaches, coughing, diarrhea and back pain. Fingolimod can also cause bradycardia, an atrioventricular block, elevated liver enzymes and macular edema. Fingolimod was approved by the FDA in 2010 as first-line therapy, and by the European Medicines Agency in 2011 as second-line therapy. Fingolimod has been available in Japan since 2011.
Initially, PML cases treated with fingolimod were identified among MS patients who had been switched from natalizumab therapy. 53 The first case of natalizumab-na€ ıve fingolimod-associated PML was reported in 2015. This MS patient showed brain MRI lesions suggestive of PML, and a positive cerebrospinal fluid analysis for JCV DNA without clinical deterioration (asymptomatic fingolimod-associated PML). 54 As of 31 May 2017, approximately 217 000 patients received fingolimod in the postmarketing setting worldwide. The overall rate of fingolimod-associated PML not attributed to previous natalizumab treatment is estimated to be less than 1:10 000 patients. There have been 15 confirmed fingolimod-associated PML cases.
55,56 Three out of the 15 patients died, and four Japanese MS patients have been identified. The occurrence of fingolimodassociated PML cases in Japanese MS patients is significant.
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Dimethyl fumarate
Dimethyl fumarate is the methyl ester of fumaric acid. Dimethyl fumarate is an immunomodulatory drug with anti-inflammatory properties; however, its mechanism of action in MS currently remains unclear. Dimethyl fumarate is known to activate the nuclear factor (erythroid-derived 2)-like 2 transcriptional pathway, which is involved in physiological responses to oxidative stress. 58 It has also been shown to upregulate nuclear factor (erythroidderived 2)-like 2-dependent anti-oxidant genes.
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Two phase III trials on RRMS showed that dimethyl fumarate reduced the ARR by 44-53%, the disability progression rate by 22-32% and MRI Gdenhanced lesions by 75-94% from that with a placebo.
60,61 A study comparing it with glatiramer acetate also reported a reduction in ARR by 24%, and a reduced rate of disability progression by 17%. Although these differences were not significant, the number of new and enlarging MRI T2 lesions was significantly reduced by approximately 36%.
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Common adverse events were flushing, nausea, diarrhea and abdominal pain. Dimethyl fumarate might also reduce white blood cell counts and elevate liver enzymes. It has been used for many years in the treatment of psoriasis. Dimethyl fumarate was approved as a first-line therapy for MS by the FDA and European Medicines Agency in 2013, and was made available in Japan in 2017.
The first PML case was reported in a psoriasis patient treated with dimethyl fumarate. In MS patients, the first PML case was published in 2015. 64 In that review, three patients including one MS patient died (16% mortality). Lymphocytopenia, particularly the loss of T cells, has been suggested as an important risk factor. In addition, "punctate lesions" (punctate pattern) on brain MRI, a characteristic sign that has been demonstrated as being very specific for natalizumabassociated PML, was observed in five psoriasis patients who developed fumarate-associated PML. The data for the five MS patients who developed dimethyl fumarate-associated PML are summarized in Table 3 .
Conclusion
Progressive multifocal leukoencephalopathy is a rare and potentially fatal complication of immunosuppression caused by disease or induced by drugs. Although MS itself is not an underlying disease of PML, several drugs used in the treatment of MS, such as natalizumab, fingolimod and dimethyl fumarate, have been implicated in the development of PML. PML risk stratification strategies are insufficient for most of the therapeutic agents for the treatment of MS because of the rarity of PML. In natalizumab-associated PML, the presence of anti-JCV antibodies; a long treatment duration, particularly that longer than 24 months; and the administration of prior immunosuppressive drugs have been identified as risk factors. In addition, anti- 
